• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小细胞肺癌进入精准医学时代。

Small cell lung cancer enters the era of precision medicine.

机构信息

Cancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester, Manchester, UK; Cancer Research UK Lung Cancer Centre of Excellence, Manchester, UK.

Cancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester, Manchester, UK; Cancer Research UK Lung Cancer Centre of Excellence, Manchester, UK.

出版信息

Cancer Cell. 2021 Mar 8;39(3):297-299. doi: 10.1016/j.ccell.2021.02.002. Epub 2021 Feb 11.

DOI:10.1016/j.ccell.2021.02.002
PMID:33577787
Abstract

In this issue of Cancer Cell, Gay et al. describe a molecular classification of small cell lung cancers and extend prior studies that highlight the potential for personalized treatments. Notably, they identify a new "inflamed" subtype that may emerge following acquired chemoresistance but which may become more susceptible to immunotherapy.

摘要

在本期《癌细胞》中,Gay 等人描述了小细胞肺癌的一种分子分类,并扩展了先前的研究,这些研究强调了个性化治疗的潜力。值得注意的是,他们发现了一种新的“炎症”亚型,这种亚型可能在获得性化疗耐药后出现,但可能对免疫疗法更敏感。

相似文献

1
Small cell lung cancer enters the era of precision medicine.小细胞肺癌进入精准医学时代。
Cancer Cell. 2021 Mar 8;39(3):297-299. doi: 10.1016/j.ccell.2021.02.002. Epub 2021 Feb 11.
2
A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization.肺癌的个体化治疗:分子途径、靶向治疗和基因组特征。
Adv Exp Med Biol. 2014;799:85-117. doi: 10.1007/978-1-4614-8778-4_5.
3
[Immuno-checkpoint inhibitor resistance and strategy in lung cancer].[肺癌中的免疫检查点抑制剂耐药性及策略]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Jul 12;43(7):603-606. doi: 10.3760/cma.j.cn112147-20200312-00319.
4
Lung cancer in the era of precision medicine.精准医学时代的肺癌
Clin Cancer Res. 2015 May 15;21(10):2213-20. doi: 10.1158/1078-0432.CCR-14-2748.
5
[Challenge of gene-based personalized lung cancer medicine].[基于基因的个性化肺癌医学面临的挑战]
Nihon Rinsho. 2015 Aug;73(8):1373-7.
6
New Therapies and Biomarkers: Are We Ready for Personalized Treatment in Small Cell Lung Cancer?新疗法和生物标志物:我们是否已准备好对小细胞肺癌进行个体化治疗?
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-10. doi: 10.1200/EDBK_320673.
7
Personalized chemotherapy of lung cancer: What the radiologist should know.肺癌的个体化化疗:放射科医生应该知道什么。
Diagn Interv Imaging. 2016 Mar;97(3):287-96. doi: 10.1016/j.diii.2015.11.013. Epub 2016 Feb 5.
8
Advances in biology and novel treatments of SCLC: The four-color problem in uncharted territory.小细胞肺癌生物学进展与新疗法:未知领域的四色问题
Semin Cancer Biol. 2022 Nov;86(Pt 2):386-395. doi: 10.1016/j.semcancer.2022.05.005. Epub 2022 May 13.
9
In Search of Lost Biomarker for Immunotherapy in Small Cell Lung Cancer.寻找小细胞肺癌免疫治疗的生物标志物。
Clin Cancer Res. 2024 Feb 16;30(4):652-654. doi: 10.1158/1078-0432.CCR-23-3087.
10
Personalized Therapy of Non-small Cell Lung Cancer (NSCLC).非小细胞肺癌(NSCLC)的个体化治疗
Adv Exp Med Biol. 2016;890:203-22. doi: 10.1007/978-3-319-24932-2_11.

引用本文的文献

1
Construction and validation of immune prognosis model for lung adenocarcinoma based on machine learning.基于机器学习的肺腺癌免疫预后模型的构建与验证
Front Oncol. 2025 Jul 22;15:1630663. doi: 10.3389/fonc.2025.1630663. eCollection 2025.
2
Midkine Promotes Tumor Growth and Attenuates the Effect of Cisplatin in Small Cell Lung Cancer.中期因子促进小细胞肺癌的肿瘤生长并减弱顺铂的作用。
Cancer Med. 2025 Jul;14(13):e71034. doi: 10.1002/cam4.71034.
3
Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study.
基于分子特征的腹膜后脂肪肉瘤分类:一项前瞻性队列研究。
Elife. 2025 May 23;14:RP100887. doi: 10.7554/eLife.100887.
4
Prediction of medication nonadherence in patients with lung cancer based on nomogram model construction.基于列线图模型构建预测肺癌患者的药物治疗不依从性
Medicine (Baltimore). 2025 Mar 21;104(12):e41900. doi: 10.1097/MD.0000000000041900.
5
Differential expression of the MYC-Notch axis drives divergent responses to the front-line therapy in central and peripheral extensive-stage small-cell lung cancer.MYC-Notch轴的差异表达驱动了中央型和外周广泛期小细胞肺癌对一线治疗的不同反应。
MedComm (2020). 2025 Feb 18;6(3):e70112. doi: 10.1002/mco2.70112. eCollection 2025 Mar.
6
Updated Bayesian network meta-analysis on the efficacy and safety of PD-1 versus PD-L1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.关于程序性死亡蛋白1(PD-1)抑制剂与程序性死亡配体1(PD-L1)抑制剂在广泛期小细胞肺癌一线化疗治疗中疗效和安全性的更新贝叶斯网络荟萃分析。
Front Oncol. 2025 Jan 28;14:1455306. doi: 10.3389/fonc.2024.1455306. eCollection 2024.
7
Novel Spatial Approaches to Dissect the Lung Cancer Immune Microenvironment.剖析肺癌免疫微环境的新型空间方法
Cancers (Basel). 2024 Dec 12;16(24):4145. doi: 10.3390/cancers16244145.
8
Small cell lung cancer with liver metastases: from underlying mechanisms to treatment strategies.小细胞肺癌伴肝转移:从基础机制到治疗策略。
Cancer Metastasis Rev. 2024 Nov 25;44(1):5. doi: 10.1007/s10555-024-10220-8.
9
Prognostic model of lung adenocarcinoma based on immunoprognosis-related genes and related drug prediction.基于免疫预后相关基因的肺腺癌预后模型及相关药物预测
J Thorac Dis. 2024 Sep 30;16(9):5860-5877. doi: 10.21037/jtd-24-569. Epub 2024 Sep 26.
10
Advances of E3 ligases in lung cancer.肺癌中E3泛素连接酶的研究进展
Biochem Biophys Rep. 2024 May 27;38:101740. doi: 10.1016/j.bbrep.2024.101740. eCollection 2024 Jul.